Enterprise Value

7.903M

Cash

80.63M

Avg Qtr Burn

-28.05M

Short % of Float

14.63%

Insider Ownership

10.82%

Institutional Own.

61.33%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Data readout

mecbotamab vedotin (BA3011) (anti-AXL ADC) Details
Solid tumor/s, Soft tissue sarcoma, Non-small cell lung carcinoma, Bone sarcoma, Cancer

Phase 2

Data readout

Phase 2

Data readout

Ozuriftamab vedotin (BA3021) (ROR2-ADC) Details
Solid tumor/s, Cancer, Head and neck squamous cell carcinoma

Phase 2

Update

Evalstotug (BA3071) + Nivolumab Details
Solid tumor/s, Cancer, Melanoma, Non-small cell lung carcinoma

Phase 1

Data readout

Phase 1

Data readout